{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:22:35Z","timestamp":1760145755214,"version":"build-2065373602"},"reference-count":129,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals International AG\u2014Singapore Branch"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The Onco Summit 2023: The Latin American (LATAM) Chapter took place over two days, from 19\u201320 May 2023, in Brazil. The event aimed to share the latest updates across various oncology disciplines, address critical clinical challenges, and exchange best practices to ensure optimal patient treatment. More than 30 international and regional speakers and more than 300 oncology specialists participated in the Summit. The Summit discussions centered on common challenges and therapeutic advances in cancer care, with a specific focus on the unique obstacles faced in LATAM and examples of adaptable strategies to address these challenges. The Summit also facilitated the establishment of a network of oncologists, hematologists, and scientists in LATAM, enabling collaboration to improve cancer care, both in this region and globally, through drug development and clinical research. This report summarizes the key discussions from the Summit for the global and LATAM oncology community.<\/jats:p>","DOI":"10.3390\/cancers16173063","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T04:06:41Z","timestamp":1725336401000},"page":"3063","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proceedings from the First Onco Summit: LATAM Chapter, 19\u201320 May 2023, Rio de Janeiro, Brazil"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"first","affiliation":[{"name":"Hematology, Faculty of Medical Sciences of Santa Casa de S\u00e3o Paulo, S\u00e3o Paulo 01224-001, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Catalan Institut Catal\u00e0 d\u2019Oncologia-L\u2019Hospitalet, Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), University of Barcelona (UB), 08908 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garcia Rosario","family":"Campelo","sequence":"additional","affiliation":[{"name":"Thoracic Tumors Unit, Medical Oncology Department, University Hospital A Coru\u00f1a Biomedical Research Institute (INIBIC), 15006 A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Aur\u00e9lio","family":"Salvino","sequence":"additional","affiliation":[{"name":"Cell Therapy, D\u2019OR Institute Research & Education (IDOR)\/PPGMS-Federal University of Bahia (UFBA), Salvador 40110-100, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Oxford Translational Myeloma Centre, NDORMS, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000530416","article-title":"The cancer treatment gap in lower- to middle-income countries","volume":"101","author":"Cardone","year":"2023","journal-title":"Oncology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","article-title":"Priorities for cancer research in low- and middle-income countries: A global perspective","volume":"28","author":"Pramesh","year":"2022","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stefan, D.C., and Tang, S. (2023). Addressing cancer care in low- to middle-income countries: A call for sustainable innovations and impactful research. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11272-9"},{"key":"ref_5","first-page":"100294","article-title":"An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean","volume":"13","author":"Laversanne","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_6","first-page":"1","article-title":"Latin America and the Caribbean code against cancer: Developing evidence-based recommendations to reduce the risk of cancer in Latin America and the Caribbean","volume":"5","author":"Cazap","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"ref_7","first-page":"100559","article-title":"A fresh perspective on Latin America cancer care: Uncovering hidden messages in unconventional data sources","volume":"24","author":"Llera","year":"2023","journal-title":"Lancet Reg. Health Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e391278","DOI":"10.1200\/EDBK_391278","article-title":"Novel immunotherapeutics: Perspectives on checkpoints, bispecifics, and vaccines in development","volume":"43","author":"Kreidieh","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: Current landscape and future perspectives","volume":"106","author":"Giugliano","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41423-021-00679-8","article-title":"Exploring innate immunity in cancer immunotherapy: Opportunities and challenges","volume":"18","author":"Li","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e000695","DOI":"10.1136\/jitc-2020-000695","article-title":"Lifting the innate immune barriers to antitumor immunity","volume":"8","author":"Rothlin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yang, L., Gu, X., Yu, J., Ge, S., and Fan, X. (2021). Oncolytic virotherapy: From bench to bedside. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.790150"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in Patients With MET-Amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","article-title":"Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas","volume":"3","author":"Drilon","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/JTO.0b013e3182629903","article-title":"A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib","volume":"7","author":"Gautschi","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Peters","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","article-title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification","volume":"6","author":"Ou","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): A glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non\u2013small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., and Roviello, G. (2022). Lung cancer immunotherapy: Beyond common immune checkpoints inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14246145"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4143\/crt.2022.078","article-title":"Challenges in the use of targeted therapies in non-small cell lung cancer","volume":"54","author":"Uprety","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: Progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1200\/JCO.2021.39.15_suppl.9046","article-title":"Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma","volume":"39","author":"Clay","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"CT089","DOI":"10.1158\/1538-7445.AM2019-CT089","article-title":"Abstract CT089: Phase Ib\/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)","volume":"79","author":"Kluger","year":"2019","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-21-4020","article-title":"First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e005471","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhou, S., Liu, M., Ren, F., Meng, X., and Yu, J. (2021). The landscape of bispecific T cell engager in cancer treatment. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00294-9"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study","volume":"41","author":"Champiat","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: Barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK Cells: What lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","article-title":"Reimagining antibody-dependent cellular cytotoxicity in cancer: The potential of natural killer cell engagers","volume":"43","author":"Pinto","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41467-023-36126-7","article-title":"Enhancing CAR-T cell functionality in a patient-specific manner","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: Platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S1602","DOI":"10.21037\/jtd.2018.05.134","article-title":"Vaccine and immune cell therapy in non-small cell lung cancer","volume":"10","author":"Oliveres","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., and Zhou, H. (2022). Biomarker-targeted therapies in non-small cell lung cancer: Current status and perspectives. Cells, 11.","DOI":"10.3390\/cells11203200"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018","volume":"16","author":"Ettinger","year":"2018","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: A CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., and Adamo, V. (2019). Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061431"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2022.06.012","article-title":"High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial","volume":"170","author":"Zwierenga","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.21037\/tlcr-22-522","article-title":"Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration","volume":"11","author":"Yang","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.21037\/tlcr-22-638","article-title":"Targeting lung cancer brain metastases: A narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease","volume":"12","author":"Nelson","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Peng, L., Zhu, L., Sun, Y., Stebbing, J., Selvaggi, G., Zhang, Y., and Yu, Z. (2022). Targeting ALK rearrangements in NSCLC: Current state of the art. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.863461"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.14694\/EdBook_AM.2013.33.327","article-title":"Lung cancer in developing countries: Access to molecular testing","volume":"33","author":"Ferreira","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_55","first-page":"e389950","article-title":"Treatment decisions for resectable non-small-cell lung cancer: Balancing less with more?","volume":"43","author":"Botticella","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.21037\/tlcr.2019.03.05","article-title":"Environmental and occupational determinants of lung cancer","volume":"8","author":"Shankar","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.122.264972","article-title":"New developments in myeloma treatment and response assessment","volume":"64","author":"Jamet","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dima, D., Jiang, D., Singh, D.J., Hasipek, M., Shah, H.S., Ullah, F., Khouri, J., Maciejewski, J.P., and Jha, B.K. (2022). Multiple myeloma therapy: Emerging trends and challenges. Cancers, 14.","DOI":"10.3390\/cancers14174082"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2012-06-430645","article-title":"Darwinian evolution and tiding clones in multiple myeloma","volume":"120","author":"Bahlis","year":"2012","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12805","article-title":"The impact of intra-clonal heterogeneity on the treatment of multiple myeloma","volume":"165","author":"Brioli","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: Translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.exphem.2020.09.196","article-title":"Mechanisms of lenalidomide sensitivity and resistance","volume":"91","author":"Karsan","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/hematology.2021000231","article-title":"Treatment of older adult or frail patients with multiple myeloma","volume":"2021","author":"Grant","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100913","DOI":"10.1016\/j.blre.2021.100913","article-title":"Reality check: Real-world evidence to support therapeutic development in hematologic malignancies","volume":"53","author":"Derman","year":"2022","journal-title":"Blood Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-020-00221-y","article-title":"Real-world evidence: Bridging gaps in evidence to guide payer decisions","volume":"5","author":"Roberts","year":"2021","journal-title":"PharmacoEconomics-Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1038\/bcj.2017.31","article-title":"Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/01.HS9.0000846568.99304.59","article-title":"P925: Impact of prior treatment exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma patients treated in routine clinical practice (the INSURE study)","volume":"6","author":"Lee","year":"2022","journal-title":"Hemasphere"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","article-title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1","volume":"102","author":"Tamas","year":"2017","journal-title":"Haematologica"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/01.HS9.0000563952.08050.24","article-title":"PS1419 Comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in routine care in the US","volume":"3","author":"Davies","year":"2019","journal-title":"HemaSphere"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_83","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2021-149787","article-title":"A phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"138","author":"Nadeem","year":"2021","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e6700375","DOI":"10.1097\/01.HS9.0000970720.67003.75","article-title":"P954: Multiple myeloma in Latin America cancer registry: The MYLACRE study","volume":"7","author":"Hungria","year":"2023","journal-title":"Hemasphere"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1182\/blood-2022-166762","article-title":"A Brazilian real-life experience of multiple myeloma patients: Final results from the Mmybrave multi-center study","volume":"140","author":"Hungria","year":"2022","journal-title":"Blood"},{"key":"ref_87","first-page":"1","article-title":"Epidemiology of hematologic malignancies in real-world settings: Findings from the Hemato-Oncology Latin America Observational registry study","volume":"5","author":"Chiattone","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","article-title":"Treatment of Hodgkin lymphoma: The past, present, and future","volume":"5","author":"Evens","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Sureda, A., Andr\u00e9, M., Borchmann, P., da Silva, M.G., Gisselbrecht, C., Vassilakopoulos, T.P., Zinzani, P.L., and Walewski, J. (2020). Improving outcomes after autologous transplantation in relapsed\/refractory Hodgkin lymphoma: A European expert perspective. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07561-2"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41375-021-01442-8","article-title":"Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: A German Hodgkin Study Group analysis","volume":"36","author":"Gillessen","year":"2022","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/bjh.16201","article-title":"Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation","volume":"188","author":"Kaloyannidis","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Takiar, R., and Karimi, Y. (2022). Novel salvage therapy options for initial treatment of relapsed\/refractory classical Hodgkin\u2019s lymphoma: So many options, how to choose?. Cancers, 14.","DOI":"10.3390\/cancers14143526"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10147-016-1045-2","article-title":"T-cell lymphomas, a challenging disease: Types, treatments, and future","volume":"22","author":"Ma","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_94","first-page":"537","article-title":"S2k-Guidelines\u2014Cutaneous lymphomas (ICD10 C82\u2013C86): Update 2021","volume":"20","author":"Dippel","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.24876","article-title":"Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Wilcox","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Maranzano, M., and Mead, M. (2023). The role of transplantation in Hodgkin lymphoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1054314"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/2040620718786833","article-title":"Update on the role of brentuximab vedotin in classical Hodgkin lymphoma","volume":"9","author":"Tomassetti","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Chatzidimitriou, C., Asimakopoulos, J.V., Arapaki, M., Tzoras, E., Angelopoulou, M.K., and Konstantopoulos, K. (2019). Immunotherapy in Hodgkin lymphoma: Present status and future strategies. Cancers, 11.","DOI":"10.3390\/cancers11081071"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.HS9.0000890960.29449.17","article-title":"T098: Brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP in patients with relapsed or refractory classical Hodgkin\u2019s lymphoma. Interim results of the BRESELIBET prospective clinical trial","volume":"6","author":"Terol","year":"2022","journal-title":"Hemasphere"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"De Filippi, R., Marcacci, G., Derenzini, E., Musso, M., Donnarumma, D., Morelli, E., Patti, C., Maraglino, A.M.E., Scalone, R., and Simeone, L. (2022). Anti-PD1 consolidation in patients with Hodgkin lymphoma at high risk of relapse after autologous stem cell transplantation: A multicenter real-life study. Cancers, 14.","DOI":"10.3390\/cancers14235846"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: The era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/OP.20.00771","article-title":"Checkpoint inhibition therapy in transplant-ineligible relapsed or refractory classic Hodgkin lymphoma","volume":"17","author":"Lee","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Randall, M.P., and Spinner, M.A. (2023). Optimizing treatment for relapsed\/refractory classic Hodgkin lymphoma in the era of immunotherapy. Cancers, 15.","DOI":"10.20944\/preprints202307.0430.v1"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.15539","article-title":"Prospective study of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy","volume":"183","author":"Walewski","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ejh.12973","article-title":"Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study","volume":"99","author":"Zagadailov","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12939-018-0748-6","article-title":"Barriers for conducting clinical trials in developing countries- a systematic review","volume":"17","author":"Alemayehu","year":"2018","journal-title":"Int. J. Equity Health"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.14694\/EdBook_AM.2015.35.e132","article-title":"The global conduct of cancer clinical trials: Challenges and opportunities","volume":"35","author":"Barrios","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_113","first-page":"100157","article-title":"Challenges of globalization of cancer drug trials\u2014Recruitment in LMICs, approval in HICs","volume":"7","author":"Gyawali","year":"2021","journal-title":"Lancet Reg. Health Am."},{"key":"ref_114","first-page":"3","article-title":"Challenges in oncology studies: Review from a global perspective","volume":"1","author":"Kaushik","year":"2019","journal-title":"Eur. J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial watch: Phase II and phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs\u2014A global crisis","volume":"20","author":"Barrios","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_117","first-page":"43","article-title":"Opportunities and challenges of implementing pharmacogenomics in cancer drug development","volume":"2","author":"Paolo","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2147\/CMAR.S420890","article-title":"Challenges and strategies for improving access to cancer drugs in Malaysia: Summary of opinions expressed at the 2nd MACR International Scientific Conference 2022","volume":"15","author":"Tan","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_119","unstructured":"Timothy, S. (2023, November 25). Weighing Two Drivers for Pharmaceutical Stocks. Available online: https:\/\/www.fisherinvestments.com\/en-us\/marketminder\/weighing-two-drivers-for-pharmaceutical-stocks."},{"key":"ref_120","first-page":"174","article-title":"Fresh from the biotech pipeline: Fewer approvals, but biologics gain share","volume":"41","author":"Senior","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/picr.picr_62_21","article-title":"Introduction to real-world evidence studies","volume":"12","author":"Chodankar","year":"2021","journal-title":"Perspect. Clin. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cell.2019.12.009","article-title":"The master observational trial: A new class of master protocol to advance precision medicine","volume":"180","author":"Dickson","year":"2020","journal-title":"Cell"},{"key":"ref_123","unstructured":"NHS (2023, November 25). Publishing Your Research Findings, Available online: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/research-planning\/publishing-your-research-findings\/."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.drudis.2022.05.018","article-title":"Open innovation: A paradigm shift in pharma R&D?","volume":"27","author":"Schuhmacher","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Yeung, A.W.K., Atanasov, A.G., Sheridan, H., Klager, E., Eibensteiner, F., V\u00f6lkl-Kernsock, S., Kletecka-Pulker, M., Willschke, H., and Schaden, E. (2021). Open innovation in medical and pharmaceutical research: A literature landscape analysis. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.587526"},{"key":"ref_126","first-page":"920","article-title":"Precision oncology in Latin America: Current situation, challenges and perspectives","volume":"13","author":"Ali","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S1470-2045(21)00492-7","article-title":"Cancer control in Latin America and the Caribbean: Recent advances and opportunities to move forward","volume":"22","author":"Barrios","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.hoc.2023.05.013","article-title":"State of cancer control in South America: Challenges and advancement strategies","volume":"38","author":"Riano","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008\u20132016","volume":"188","author":"Miguel","year":"2020","journal-title":"Br. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3063\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:47:38Z","timestamp":1760111258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":129,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cancers16173063"],"URL":"https:\/\/doi.org\/10.3390\/cancers16173063","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}